Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitations of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the BVS versus DES beyond 2 years are emerging.
Objective: To study mid-term outcomes.
Methods: We searched online databases (PubMed/Medline, Embase, CENTRAL), several websites, meeting presentations and scientific session abstracts until August 8th, 2017 for studies comparing Absorb BVS with second-generation DES. The primary outcome was target lesion failure (TLF). Secondary outcomes were all-cause mortality, myocardial infarction, target lesion revascularization (TLR) and definite/probable device thrombosis. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived using a random effects model.
Results: Ten studies, seven randomized controlled trials and three propensity-matched observational studies, with a total of 7320 patients (BVS n = 4007; DES n = 3313) and a median follow-up duration of 30.5 months, were included. Risk of TLF was increased for BVS-treated patients (OR 1.34 [95% CI: 1.12-1.60], p = 0.001, I2 = 0%). This was also the case for all myocardial infarction (1.58 [95% CI: 1.27-1.96], p<0.001, I2 = 0%), TLR (1.48 [95% CI: 1.19-1.85], p<0.001, I2 = 0%) and definite/probable device thrombosis (of 2.82 (95% CI: 1.86-3.89], p<0.001 and I2 = 40.3%). This did not result in a difference in all-cause mortality (0.78 [95% CI: 0.58-1.04], p = 0.09, I2 = 0%). OR for very late (>1 year) device thrombosis was 6.10 [95% CI: 1.40-26.65], p = 0.02).
Conclusion: At mid-term follow-up, BVS was associated with an increased risk of TLF, MI, TLR and definite/probable device thrombosis, but this did not result in an increased risk of all-cause mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942828 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197119 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Bioresorbable scaffolds advances, challenges, and future directions.
Ann Med Surg (Lond)
July 2025
Department of Internal Medicine, Trinity Medical Sciences University School of Medicine, Ratho Mill Kingstown, Saint Vincent and the Grenadines.
Over the past few decades, researchers have attempted to overcome the disadvantages of metallic stents. This led to the birth of the first "Bioresorbable Scaffold" (BRS) model, the Absorb Bioresorbable Vascular Scaffold (BVS), in 1999 by Abbott. A stent that spontaneously resorbs shows a promising theoretical minimal risk of long-term stent thrombosis and omits the need for long-term antiplatelet therapy.
View Article and Find Full Text PDF3D-Printed CNT-Reinforced Bioresorbable Vascular Scaffold with Enhanced Mechanical Stability and Integrated Wireless Pressure Sensor for Continuous Hemodynamic Monitoring.
ACS Sens
August 2025
MEMS and Nanotechnology Laboratory, School of Mechanical Engineering, Chonnam National University, Gwangju 61186, Republic of Korea.
Polymer-based bioresorbable vascular scaffolds (BVS) have garnered significant attention in biomedical applications. Among various BVS, polycaprolactone (PCL)-based scaffolds exhibit excellent biocompatibility, flexibility, chemical stability, and controlled degradation. However, their low radial strength limits practical applicability.
View Article and Find Full Text PDFLess Is More?: Bioresorbable Vascular Scaffold vs Drug-Eluting Metallic Stent: 10-Year Follow-Up.
JACC Case Rep
May 2025
Division of Cardiology, Department of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong. Electronic address:
Background: ABSORB bioresorbable vascular scaffold (BVS) emerged in 2012 aiming to provide early mechanical support while restoring normal vascular function after its complete resorption. Subsequent trials raised safety concerns over early higher scaffold thrombosis rates compared with metallic drug-eluting stent (DES). However, very long-term outcomes of BVS remain insufficiently reported.
View Article and Find Full Text PDFOCT-Guided covered stent implantation for acquired coronary aneurysm after bioresorbable vascular scaffold: case report.
Future Cardiol
April 2025
Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Coronary artery aneurysm (CAA) formation following bioresorbable vascular scaffold (BVS) implantation is a rare but serious complication with no clear treatment guidelines. We report the case of a 56-year-old man with coronary artery disease (CAD) and a chronic total occlusion (CTO) in the left anterior descending artery (LAD) underwent full revascularization with BVS in 2016. Seven years later, he experienced recurrent angina, and angiography revealed 80% stenosis in the proximal LAD and a large coronary aneurysm in the middle LAD.
View Article and Find Full Text PDFEarly and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.